IMMUCELL CORP /DE/
Business
ImmuCell Corporation develops, manufactures and sells animal health products that protect newborn calves and address mastitis in dairy cows. Its main offerings include the USDA‑licensed First Defense® product line (including Tri‑Shield® and Dual‑Force®), First Defense Technology® formats, a California Mastitis Test (CMT) and a purified Nisin intramammary treatment (Re‑Tain®). The company reports results across three segments—Scours, Mastitis and Other—and focuses on product development, manufacturing and regulatory compliance. It distributes primarily through major animal‑health distributors to veterinary clinics, fleet stores and farms in North America and select international markets.
Summary from filing dated 2025-03-28
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Product sales | 28 | 26 | — | — | — | |
| Costs of goods sold | 16 | 19 | — | — | — | |
| Gross profit | 11 | 8 | 4 | 8 | 9 | |
| Product development expenses | 3 | 4 | 4 | 4 | 4 | |
| Sales and marketing expenses | 4 | 3 | 3 | 3 | 3 | |
| Administrative expenses | 3 | 2 | 2 | 2 | 2 | |
| Operating expenses | 10 | 10 | 10 | 10 | 8 | |
| NET OPERATING INCOME (LOSS) | 2 | −2 | −6 | −2 | 257,385 | |
| Other expenses, net | 3 | 506,414 | 21,893 | — | — | |
| LOSS BEFORE INCOME TAXES | −1 | −2 | −6 | −2 | −69,127 | |
| Income tax expense | 11,570 | 10,056 | 4,627 | 7,672 | 9,165 | |
| NET LOSS | −1 | −2 | −6 | −2 | −78,292 | |
| Basic weighted average common shares outstanding (in shares) | 9 | 8 | 8 | 8 | 8 | |
| Basic net loss per share (in dollars per share) | −0.12 | −0.26 | −0.75 | −0.32 | −0.01 | |
| Diluted weighted average common shares outstanding (in shares) | 9 | 8 | 8 | 8 | 8 | |
| Diluted net loss per share (in dollars per share) | −0.12 | −0.26 | −0.75 | −0.32 | −0.01 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2023 2023-10-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 4 | 4 | 978,741 | — | 6 | |
| Trade accounts receivable | 3 | 4 | 2 | — | 2 | |
| Inventory | 9 | 7 | 8 | — | 6 | |
| Prepaid expenses and other current assets | 451,673 | 400,762 | 493,885 | — | 406,055 | |
| Total current assets | 17 | 15 | 11 | — | 14 | |
| Property, plant and equipment, net | 21 | 25 | 28 | — | 28 | |
| Operating lease right-of-use asset | 4 | 5 | 5 | — | 2 | |
| Goodwill | 95,557 | 95,557 | 95,557 | — | 95,557 | |
| Intangible assets, net | 0 | 19,104 | 38,208 | — | 57,312 | |
| Other assets | 37,686 | 33,368 | 57,655 | — | 14 | |
| TOTAL ASSETS | 43 | 45 | 44 | — | 45 | |
| Current portion of debt obligations | 2 | 1 | — | — | — | |
| Current portion of operating lease liability | 85,489 | 432,072 | 644,276 | — | 31,764 | |
| Accounts payable and accrued expenses | 2 | 2 | 2 | — | 2 | |
| Total current liabilities | 4 | 4 | 4 | — | 3 | |
| Debt obligations, net of current portion | 7 | 9 | — | — | — | |
| Operating lease liability, net of current portion | 4 | 4 | 4 | 5 | 2 | |
| Total long-term liabilities | 11 | 13 | 15 | — | 11 | |
| TOTAL LIABILITIES | 15 | 18 | 19 | — | 14 | |
| COMMITMENTS AND CONTINGENCIES (See Note 10) | — | — | — | — | — | |
| Common stock, $0.10 par value per share, with 15,000,000 shares authorized and 9,105,622 and 9,042,392 shares issued and 9,045,851 and 8,979,091 shares outstanding as of December 31, 2025 and 2024, respectively | 910,563 | 904,240 | 781,417 | — | 781,417 | |
| Additional paid-in capital | 41 | 41 | 36 | — | 36 | |
| Accumulated deficit | −15 | −14 | −12 | — | −6 | |
| Treasury stock, at cost, 59,771 and 63,301 shares as of December 31, 2025 and 2024, respectively | −130,760 | −138,482 | −138,482 | — | −147,233 | |
| Total stockholders equity | 27 | 28 | 25 | — | 30 | |
| TOTAL LIABILITIES AND STOCKHOLDERS EQUITY | 43 | 45 | 44 | — | 45 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation | 3 | 3 | 3 | 2 | 2 | |
| Amortization of intangible assets | 19,104 | 19,104 | 19,104 | 19,104 | — | |
| Amortization and write-off of debt issuance costs and debt discounts | 54,348 | 42,666 | — | — | — | |
| Share-based compensation | 295,871 | 325,551 | 368,866 | 266,244 | — | |
| Loss on disposal of property, plant and equipment | 106,350 | 15,391 | 8,099 | −7,334 | — | |
| Impairment charge related to property, plant and equipment | 3 | 0 | — | — | — | |
| Non-cash rent benefit | −284,846 | −149,741 | — | — | — | |
| Trade accounts receivable | 352,124 | −2 | −426,783 | 935,629 | — | |
| Inventory | −2 | 699,218 | −2 | −3 | −997,460 | |
| Prepaid expenses and other current assets | −50,911 | 93,123 | −87,830 | −110,858 | 26,064 | |
| Other assets | −4,318 | 24,287 | — | — | — | |
| Accounts payable and accrued expenses | −195,254 | 362,606 | 156,995 | 341,614 | 245,760 | |
| Net cash provided by operating activities | 2 | 357,903 | −5 | −2 | 954,170 | |
| Purchase of property, plant and equipment | −1 | −465,725 | −2 | −4 | −3 | |
| Proceeds from sale of property, plant and equipment | 36,132 | 4,500 | 2,474 | 11,000 | — | |
| Net cash used for investing activities | −1 | −461,225 | −2 | −4 | −2 | |
| Borrowings on bank debt | 801,267 | 0 | — | — | — | |
| Repayments on bank debt | −2 | −1 | −1 | −897,125 | −768,271 | |
| Payments of debt issuance costs and debt discounts | −14,633 | −5,037 | −35,425 | −19,306 | — | |
| Proceeds from At-The-Market Offering | 349,326 | 5 | — | — | 165,337 | |
| Payments of equity issuance fees | −67,880 | −291,834 | — | — | — | |
| Proceeds from exercise of stock options | 3 | 0 | 18,760 | 30,670 | 11,693 | |
| Net cash (used for) provided by financing activities | −1 | 3 | 2 | 1 | 4 | |
| NET INCREASE IN CASH AND CASH EQUIVALENTS | 48,599 | 3 | — | — | — | |
| Income taxes | 10,691 | 7,293 | — | — | — | |
| Interest | 443,019 | 528,907 | 444,954 | 338,516 | 308,682 | |
| Change in capital expenditures incurred, but not paid | 4,685 | 4,421 | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is IMMUCELL CORP /DE/'s CIK number?
IMMUCELL CORP /DE/'s SEC CIK number is 0000811641 (811641). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find IMMUCELL CORP /DE/'s SEC filings?
All of IMMUCELL CORP /DE/'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did IMMUCELL CORP /DE/ last report earnings?
IMMUCELL CORP /DE/ (ICCC) most recently filed an earnings 8-K with the SEC on Jul 9, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001437749-26-023199). This is IMMUCELL CORP /DE/'s most recent earnings filing of record — not a forecast of its next earnings date.
What is IMMUCELL CORP /DE/'s most recent earnings 8-K?
IMMUCELL CORP /DE/'s latest earnings 8-K (Item 2.02) was filed Jul 9, 2026 under accession 0001437749-26-023199. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View IMMUCELL CORP /DE/'s latest earnings 8-K →
Look up any company's CIK number →